JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.65B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.08B |
| 3 |
Microsoft
MSFT
|
+$2.05B |
| 4 |
Vanguard Total International Bond ETF
BNDX
|
+$1.64B |
| 5 |
Micron Technology
MU
|
+$1.39B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMJ
JP Morgan Alerian MLP Index ETN 5/24/24
AMJ
|
+$2.4B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.11B |
| 3 |
Progressive
PGR
|
+$1.64B |
| 4 |
Salesforce
CRM
|
+$1.54B |
| 5 |
Adobe
ADBE
|
+$1.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.15% |
| 2 | Technology | 24.03% |
| 3 | Healthcare | 9.24% |
| 4 | Consumer Discretionary | 8.79% |
| 5 | Financials | 8.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5276
CALL
Fastly Inc
FSLY
$4.3B
| $98.8K | ﹤0.01% |
13,400
-2,300
| -15% | -$22.5K |
2024 Q1
1 quarter
|
|
5277
Microvision
MVIS
$45.6M
| $98.7K | ﹤0.01% |
6,208
-14,757
| -70% | -$291K |
2016 Q4
30 quarters
|
|
|
CTEV
5278
Claritev Corp
CTEV
$370M
| $98.6K | ﹤0.01% |
6,346
-50,648
| -89% | -$1.21M |
2020 Q3
15 quarters
|
|
|
INZY
5279
DELISTED
Inozyme Pharma
INZY
| $98.5K | ﹤0.01% |
22,077
-39,500
| -64% | -$192K |
2020 Q3
15 quarters
|
|
5280
Omeros
OMER
$1.35B
| $98.4K | ﹤0.01% |
24,233
-2,395
| -9% | -$8.56K |
2017 Q4
26 quarters
|
|
5281
Virginia National Bankshares
VABK
$262M
| $98.2K | ﹤0.01% |
2,994
-3,597
| -55% | -$105K |
2023 Q1
5 quarters
|
|
5282
FT Vest US Equity Moderate Buffer ETF September
GSEP
$364M
| $97.8K | ﹤0.01% |
+2,894
| New | +$96.2K |
2024 Q2
0 quarters
|
|
|
SPWRW
5283
SunPower Inc Warrants
SPWRW
$395K
| – | – |
0
| – | – |
2023 Q2
4 quarters
|
|
5284
Innovator US Equity Ultra Buffer ETF October
UOCT
$181M
| $97.6K | ﹤0.01% |
2,848
| – | – |
2023 Q4
2 quarters
|
|
5285
Northern Technologies International Corp
NTIC
$74.1M
| $97.6K | ﹤0.01% |
5,892
+5,098
| +642% | +$84.7K |
2023 Q3
3 quarters
|
|
5286
iShares Global Consumer Staples ETF
KXI
$1.1B
| $97.4K | ﹤0.01% |
1,620
-4,488
| -73% | -$273K |
2020 Q1
17 quarters
|
|
5287
Invesco Pharmaceuticals ETF
PJP
$544M
| $97.3K | ﹤0.01% |
1,184
-2,981
| -72% | -$237K |
2023 Q2
4 quarters
|
|
5288
Codexis
CDXS
$153M
| $96.6K | ﹤0.01% |
31,172
-12,242
| -28% | -$39.3K |
2017 Q3
27 quarters
|
|
|
AEVA
5289
Aeva Technologies
AEVA
$1.02B
| $96.5K | ﹤0.01% |
38,285
+792
| +2% | +$2.58K |
2021 Q2
12 quarters
|
|
|
HUDAR
5290
DELISTED
Hudson Acquisition I Corp. Right
HUDAR
| $96K | ﹤0.01% |
400,000
-11,861
| -3% | -$2.94K |
2023 Q4
2 quarters
|
|
5291
Invesco Zacks Mid-Cap ETF
CZA
$171M
| $96K | ﹤0.01% |
983
-40
| -4% | -$3.94K |
2016 Q4
30 quarters
|
|
5292
CALL
VF Corp
VFC
$5.6B
| $95.8K | ﹤0.01% |
7,100
| – | – |
2023 Q4
2 quarters
|
|
5293
TScan Therapeutics
TCRX
$22.2M
| $95.7K | ﹤0.01% |
16,364
-50,649
| -76% | -$399K |
2023 Q4
2 quarters
|
|
5294
Fidelity MSCI Utilities Index ETF
FUTY
$2.13B
| $95.3K | ﹤0.01% |
2,168
-5,540
| -72% | -$245K |
2022 Q4
6 quarters
|
|
5295
Mama's Creations
MAMA
$616M
| $94.5K | ﹤0.01% |
14,025
-107,000
| -88% | -$652K |
2023 Q3
3 quarters
|
|
5296
CALL
Syndax Pharmaceuticals
SNDX
$1.6B
| $94.4K | ﹤0.01% |
4,600
| – | – |
2024 Q1
1 quarter
|
|
5297
ADC Therapeutics
ADCT
$140M
| $94.3K | ﹤0.01% |
+29,837
| New | +$119K |
2024 Q2
0 quarters
|
|
|
LPSN
5298
DELISTED
LivePerson
LPSN
| $93.8K | ﹤0.01% |
10,773
+8,721
| +425% | +$83.8K |
2016 Q3
31 quarters
|
|
|
LENZ
5299
LENZ Therapeutics
LENZ
$115M
| $93.7K | ﹤0.01% |
5,420
+3,738
| +222% | +$65.3K |
2021 Q3
11 quarters
|
|
5300
Trevi Therapeutics
TRVI
$2.05B
| $93.4K | ﹤0.01% |
31,350
+5,887
| +23% | +$16.4K |
2023 Q2
4 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2024 Portfolio in Review
As of Q2 2024, JP Morgan Chase held 7,917 positions worth $1.22T, up 3% from $1.18T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q2 2024 filing shows 549 new, 2,506 increased, 3,286 reduced and 578 closed positions. Its largest new stake was BlackRock Flexible Income ETF: 6,829,171 shares worth $357M. The largest sale was JP Morgan Alerian MLP Index ETN 5/24/24, an estimated $2.4B.
By sector, the portfolio is most concentrated in Miscellaneous at 24% of assets, down from 25% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2024 buy was BlackRock Flexible Income ETF: 6,829,171 shares worth $357M.
- JP Morgan Chase added most to Apple in Q2 2024, an estimated $4.65B increase.
- JP Morgan Chase's biggest Q2 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $2.11B.
- JP Morgan Chase fully exited JP Morgan Alerian MLP Index ETN 5/24/24 in Q2 2024, selling an estimated $2.4B.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.22T portfolio in Q2 2024.
- JP Morgan Chase opened 549 new positions and closed 578 in Q2 2024.
- JP Morgan Chase's portfolio value rose 3% quarter-over-quarter to $1.22T.
Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.